Don't forget the most recent 10Q
Bioheart Reports Significant Revenue Increases
SUNRISE, FL--(Marketwired - May 15, 2014) - Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced today its financial results for the first quarter of 2014.
Product revenues during the first quarter of 2014 were $322,572, compared to $4,192 during the first quarter of 2013. In addition, this is a 98% increase over the fourth quarter revenue of $157,055. The revenues recognized to date are related to sales of MyoCath, patient treatments, AdipoCell system and related supplies, and cell culturing and banking services. Cost of sales consists of the costs associated with the production of MyoCath, laboratory supplies necessary for laboratory services, production of AdipoCell systems and materials, and clinic supplies required for patient studies. Cost of sales was $94,446 in the three-month period ended March 31, 2014, which is a gross margin of 71%.
"A solid team and business plan has led to this strong start to 2014," said Mike Tomas, President and Chief Executive Officer of Bioheart. "We have already made great progress and are poised for continued momentum."